The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial
DiscussionThe trial is designed to test the hypothesis that treating IPF patients with co-trimoxazole will increase the time to death (all causes), lung transplant or first non-elective hospital admission compared to standard care (https://www.nice.org.uk/guidance/cg163), in patients with moderate to severe disease.The mechanistic aims are to investigate the effect on lung microbiota and other measures of infection, markers of epithelial injury and markers of neutrophil activity.Trial registrationInternational Standard Randomised Controlled Trials Number (ISRCTN) Registry, ID:17464641. Registered on 29 January 2015.
Source: Trials - Category: Research Source Type: clinical trials
More News: Biochemistry | Clinical Trials | Databases & Libraries | Depression | Folic Acid | Hospitals | Interstitial Lung Disease | Lung Transplant | Microbiology | National Institute for Health and Clinical Excelle | Research | Spirometry | Statistics | Study | Transplant Surgery | Transplants | Vitamin B9